New Orleans—Active surveillance for men with low-risk prostate cancer has made it to prime time.
That was the message of Stacy Loeb, MD, who moderated a press conference at the AUA annual meeting, where four studies documented the increasing popularity and safety of active surveillance in managing low-risk disease. The panel included experts from Johns Hopkins University in Baltimore, the University of California, Los Angeles, and New York University, New York, where Dr. Loeb is assistant professor of urology.
For years, Dr. Loeb said prostate cancer has been over-diagnosed and over-treated, but recent data suggest that active surveillance is helping to address the problem.
“Active surveillance use is really expanding rapidly. It has finally hit the prime time and is not experimental treatment anymore. Now, this is really what we should be promoting for our patients,” Dr. Loeb told Urology Times.